This morning, at 11:00 am Scancell Holdings plc, (AIM: SCLP), will be hosting a presentation for investors and analysts. This presentation contains no new financial information and will be available from the Company’s website. www.scancell.co.uk
Scancell Holdings Plc
Dr Richard Goodfellow / Professor Lindy Durrant
+ 44 (0)207 653 9850*
Newgate Threadneedle (Financial PR)
Guy McDougall / Heather Armstrong
+ 44 (0)207 653 9850
Zeus Capital - Nominated Adviser / Joint Broker
Ross Andrews / Tom Rowley
+ 44 (0)161 831 1512
XCAP - Joint Broker
Jon Belliss/ Adrian Kirk
+44 (0) 207 101 7070
* calls to this number will reach Newgate Threadneedle, at Scancell's instruction
Scancell is developing novel therapeutic vaccines for the treatment of cancer and infectious diseases based on its groundbreaking ImmunoBody® technology platform. Scancell’s first cancer vaccine SCIB1, which entered clinical trials in 2010, is being developed for the treatment of melanoma.
Treating cancer by vaccination allows small non-toxic doses of a vaccine to be administered to a patient, stimulating an immune response. Effective cancer vaccines need to target dendritic cells to stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
A limitation of many cancer vaccines currently in development is that they cannot specifically target dendritic cells in vivo. Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing them with tumour antigens and re-infusing them. However, this procedure is patient specific, time consuming and expensive. Scancell has developed its breakthrough patent protected ImmunoBody® technology to overcome these limitations.
An ImmunoBody® is a human antibody or fusion protein engineered to express helper cell and CTL epitopes from tumour antigens over-expressed by cancer cells. Antibodies are ideal vectors for carrying T cell epitopes from tumour antigens as they have long half-lives and can effectively target dendritic cells via their Fc receptors, allowing efficient stimulation of both helper and CTL responses.
The Immunobody® technology can be adapted to provide the basis for treating any tumour type and may also be of potential utility in the development of vaccines against hepatitis, HIV and other chronic infectious diseases.
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
Tue, 25 Sep 2018 06:20:00
The company first teamed up with Sweden's world-leading medical research university two years ago
Thu, 09 Aug 2018 08:15:00
It has exercised an option on TriGrid, which was developed by Ichor Medical Systems
Wed, 18 Jul 2018 06:09:00